CpG ODN G9.1 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses

This study examined the protective efficacy of and immune response to a nasal influenza vaccine combined with a novel mucosal oligodeoxynucleotide (ODN) adjuvant, CpG ODN G9.1 (G9.1), in a model of infection limited to the upper respiratory tract (URT) and a model of infection in the lower respirato...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2019-08, Vol.37 (36), p.5382-5389
Hauptverfasser: Tateishi, Koichiro, Fujihashi, Kohtaro, Yamamoto, Norio, Hasegawa, Hideki, Ainai, Akira, Sato, Kayoko, Iho, Sumiko, Yamamoto, Saburo, Maeyama, Jun-ichi, Odagiri, Takato, Asanuma, Hideki
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!